Average Return on Equity (ROE)
The latest reported return on equity (roe) is 16.31% as of Wednesday, December 31, 2025, shown against its trailing averages.
PODD Average Return on Equity (ROE)
PODD Return on Equity (ROE) Averages
RETURN ON EQUITY (ROE) LATEST REPORTED
16.31%
RETURN ON EQUITY (ROE) TTM
25.41%
RETURN ON EQUITY (ROE) 3Y
19.99%
RETURN ON EQUITY (ROE) 5Y
14.02%
RETURN ON EQUITY (ROE) 10Y
-16.15%
RETURN ON EQUITY (ROE) 15Y
-23.27%
RETURN ON EQUITY (ROE) 20Y
-35.27%
About Insulet Corp.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Ashley A. McEvoy